Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Low Levels of Amlodipine in Breast Milk and Plasma.

Aoki H, Ito N, Kaniwa N, Saito Y, Wada Y, Nakajima K, Sago H, Murashima A, Okamoto A, Ito S.

Breastfeed Med. 2018 Nov;13(9):622-626. doi: 10.1089/bfm.2018.0158. Epub 2018 Sep 28.

PMID:
30265578
2.

SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1.

Sato Y, Ueno H, Ioka T, Ohkawa S, Ikeda M, Shimamura T, Tsuji A, Tsuchiya Y, Furuse J, Ishii H, Furuya K, Iguchi H, Saito Y, Kaniwa N, Sawada JI, Sakamoto H, Sekine A, Okusaka T, Yoshida T; GEST.

Pancreas. 2018 May/Jun;47(5):637-642. doi: 10.1097/MPA.0000000000001052.

PMID:
29683977
3.

Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.

Hasunuma T, Tohkin M, Kaniwa N, Jang IJ, Yimin C, Kaneko M, Saito Y, Takeuchi M, Watanabe H, Yamazoe Y, Uyama Y, Kawai S.

Br J Clin Pharmacol. 2016 Jun;81(6):1078-90. doi: 10.1111/bcp.12884. Epub 2016 Mar 14.

4.

Development of a simple genotyping method for the HLA-A*31:01-tagging SNP in Japanese.

Maekawa K, Nakamura R, Kaniwa N, Mizusawa S, Kitamoto A, Kitamoto T, Ukaji M, Matsuzawa Y, Sugiyama E, Uchida Y, Kurose K, Ueta M, Sotozono C, Ikeda H, Yagami A, Matsukura S, Kinoshita S, Muramatsu M, Ikezawa Z, Sekine A, Furuya H, Takahashi Y, Matsunaga K, Aihara M, Saito Y; Japan Pharmacogenomics Data Science Consortium.

Pharmacogenomics. 2015;16(15):1689-99. doi: 10.2217/pgs.15.115. Epub 2015 Oct 2.

PMID:
26490229
5.

Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method.

Takahashi H, Kaniwa N, Saito Y, Sai K, Hamaguchi T, Shirao K, Shimada Y, Matsumura Y, Ohtsu A, Yoshino T, Doi T, Takahashi A, Odaka Y, Okuyama M, Sawada J, Sakamoto H, Yoshida T.

BMC Cancer. 2015 Oct 16;15:718. doi: 10.1186/s12885-015-1721-z.

6.

Drugs causing severe ocular surface involvements in Japanese patients with Stevens-Johnson syndrome/toxic epidermal necrolysis.

Kaniwa N, Ueta M, Nakamura R, Okamoto-Uchida Y, Sugiyama E, Maekawa K, Takahashi Y, Furuya H, Yagami A, Matsukura S, Ikezawa Z, Matsunaga K, Sotozono C, Aihara M, Kinoshita S, Saito Y.

Allergol Int. 2015 Oct;64(4):379-81. doi: 10.1016/j.alit.2015.05.002. No abstract available.

7.

[Utilization of Genomic Biomarkers for Post-marketing Safety of Drugs].

Kaniwa N.

Yakugaku Zasshi. 2015;135(5):671-9. doi: 10.1248/yakushi.14-00230-4. Review. Japanese.

8.

IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement.

Ueta M, Sawai H, Sotozono C, Hitomi Y, Kaniwa N, Kim MK, Seo KY, Yoon KC, Joo CK, Kannabiran C, Wakamatsu TH, Sangwan V, Rathi V, Basu S, Ozeki T, Mushiroda T, Sugiyama E, Maekawa K, Nakamura R, Aihara M, Matsunaga K, Sekine A, Gomes JÁ, Hamuro J, Saito Y, Kubo M, Kinoshita S, Tokunaga K.

J Allergy Clin Immunol. 2015 Jun;135(6):1538-45.e17. doi: 10.1016/j.jaci.2014.12.1916. Epub 2015 Feb 8.

PMID:
25672763
9.

Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.

Takahashi H, Sai K, Saito Y, Kaniwa N, Matsumura Y, Hamaguchi T, Shimada Y, Ohtsu A, Yoshino T, Doi T, Okuda H, Ichinohe R, Takahashi A, Doi A, Odaka Y, Okuyama M, Saijo N, Sawada J, Sakamoto H, Yoshida T.

PLoS One. 2014 Aug 15;9(8):e105160. doi: 10.1371/journal.pone.0105160. eCollection 2014.

10.
11.

Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.

Chung WH, Chang WC, Lee YS, Wu YY, Yang CH, Ho HC, Chen MJ, Lin JY, Hui RC, Ho JC, Wu WM, Chen TJ, Wu T, Wu YR, Hsih MS, Tu PH, Chang CN, Hsu CN, Wu TL, Choon SE, Hsu CK, Chen DY, Liu CS, Lin CY, Kaniwa N, Saito Y, Takahashi Y, Nakamura R, Azukizawa H, Shi Y, Wang TH, Chuang SS, Tsai SF, Chang CJ, Chang YS, Hung SI; Taiwan Severe Cutaneous Adverse Reaction Consortium; Japan Pharmacogenomics Data Science Consortium.

JAMA. 2014 Aug 6;312(5):525-34. doi: 10.1001/jama.2014.7859.

PMID:
25096692
12.

Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement.

Ueta M, Kaniwa N, Sotozono C, Tokunaga K, Saito Y, Sawai H, Miyadera H, Sugiyama E, Maekawa K, Nakamura R, Nagato M, Aihara M, Matsunaga K, Takahashi Y, Furuya H, Muramatsu M, Ikezawa Z, Kinoshita S.

Sci Rep. 2014 Apr 30;4:4862. doi: 10.1038/srep04862.

13.

[Biomarker exploration and its clinical use].

Saito Y, Sai K, Kaniwa N, Tajima Y, Ishikawa M, Nishimaki-Mogami T, Maekawa K.

Yakugaku Zasshi. 2013;133(12):1373-9. Review. Japanese.

14.

Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects.

Kaniwa N, Sugiyama E, Saito Y, Kurose K, Maekawa K, Hasegawa R, Furuya H, Ikeda H, Takahashi Y, Muramatsu M, Tohkin M, Ozeki T, Mushiroda T, Kubo M, Kamatani N, Abe M, Yagami A, Ueta M, Sotozono C, Kinoshita S, Ikezawa Z, Matsunaga K, Aihara M; Japan Pharmacogenomics Data Science Consortium.

Pharmacogenomics. 2013 Nov;14(15):1821-31. doi: 10.2217/pgs.13.180.

PMID:
24236482
15.

Genetic factors associated with gemcitabine pharmacokinetics, disposition, and toxicity.

Knights J, Sato Y, Kaniwa N, Saito Y, Ueno H, Ramanathan M.

Pharmacogenet Genomics. 2014 Jan;24(1):15-25. doi: 10.1097/FPC.0000000000000016.

PMID:
24225399
16.

Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data.

Takahashi H, Kaniwa N, Saito Y, Sai K, Hamaguchi T, Shirao K, Shimada Y, Matsumura Y, Ohtsu A, Yoshino T, Takahashi A, Odaka Y, Okuyama M, Sawada J, Sakamoto H, Yoshida T.

J Biosci Bioeng. 2013 Dec;116(6):768-73. doi: 10.1016/j.jbiosc.2013.05.021. Epub 2013 Jun 29.

PMID:
23816762
17.

Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.

Kaniwa N, Saito Y.

J Hum Genet. 2013 Jun;58(6):317-26. doi: 10.1038/jhg.2013.37. Epub 2013 May 2. Review.

PMID:
23635947
18.

Pharmacogenomics of severe cutaneous adverse reactions.

Kaniwa N, Saito Y.

Pharmacogenomics. 2013 Apr;14(6):595-8. doi: 10.2217/pgs.13.27. No abstract available.

PMID:
23570461
19.

Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant.

Tada M, Ishii-Watabe A, Maekawa K, Fukushima-Uesaka H, Kurose K, Suzuki T, Kaniwa N, Sawada J, Kawasaki N, Nakajima TE, Kato K, Yamada Y, Shimada Y, Yoshida T, Ura T, Saito M, Muro K, Doi T, Fuse N, Yoshino T, Ohtsu A, Saijo N, Okuda H, Hamaguchi T, Saito Y, Matsumura Y.

Immunogenetics. 2012 Dec;64(12):869-77. doi: 10.1007/s00251-012-0646-9. Epub 2012 Aug 18.

PMID:
22903236
20.
21.

[Current movements of four serious adverse events induced by medicinal drugs based on spontaneous reports in Japan].

Sudo C, Azuma Y, Maekawa K, Kaniwa N, Sai K, Saito Y.

Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 2011;(129):111-7. Japanese.

PMID:
22259851
22.

A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.

Tohkin M, Kaniwa N, Saito Y, Sugiyama E, Kurose K, Nishikawa J, Hasegawa R, Aihara M, Matsunaga K, Abe M, Furuya H, Takahashi Y, Ikeda H, Muramatsu M, Ueta M, Sotozono C, Kinoshita S, Ikezawa Z; Japan Pharmacogenomics Data Science Consortium.

Pharmacogenomics J. 2013 Feb;13(1):60-9. doi: 10.1038/tpj.2011.41. Epub 2011 Sep 13.

PMID:
21912425
23.

Genetic variation and haplotype structures of the glutathione S-transferase genes GSTA1 and GSTA2 in Japanese colorectal cancer patients.

Maekawa K, Hamaguchi T, Saito Y, Tatewaki N, Kurose K, Kaniwa N, Eguchi Nakajima T, Kato K, Yamada Y, Shimada Y, Yoshida T, Kamatani N, Ura T, Saito M, Muro K, Fuse N, Yoshino T, Doi T, Otsu A, Saijo N, Sawada J, Okuda H, Matsumura Y.

Drug Metab Pharmacokinet. 2011;26(6):646-58. doi: 10.2133/dmpk.DMPK-11-SC-050. Epub 2011 Aug 16.

24.

[Exploratory study on biomarkers associated with severe cutaneous adverse reactions].

Kaniwa N.

Yakugaku Zasshi. 2011 Feb;131(2):255-61. Review. Japanese.

25.

HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.

Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R; JSAR research group.

Epilepsia. 2010 Dec;51(12):2461-5. doi: 10.1111/j.1528-1167.2010.02766.x. Epub 2010 Nov 3.

26.

Genetic polymorphisms and haplotypes of por, encoding cytochrome p450 oxidoreductase, in a Japanese population.

Saito Y, Yamamoto N, Katori N, Maekawa K, Fukushima-Uesaka H, Sugimoto D, Kurose K, Sai K, Kaniwa N, Sawada J, Kunitoh H, Ohe Y, Yoshida T, Matsumura Y, Saijo N, Okuda H, Tamura T.

Drug Metab Pharmacokinet. 2011;26(1):107-16. Epub 2010 Nov 12.

27.

Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis.

Ishii-Watabe A, Saito Y, Suzuki T, Tada M, Ukaji M, Maekawa K, Kurose K, Kaniwa N, Sawada J, Kawasaki N, Yamaguchi T, Nakajima TE, Kato K, Yamada Y, Shimada Y, Yoshida T, Ura T, Saito M, Muro K, Doi T, Fuse N, Yoshino T, Ohtsu A, Saijo N, Hamaguchi T, Okuda H, Matsumura Y.

Drug Metab Pharmacokinet. 2010;25(6):578-87. Epub 2010 Oct 1.

28.

Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.

Sai K, Saito Y, Tatewaki N, Hosokawa M, Kaniwa N, Nishimaki-Mogami T, Naito M, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Tamura T, Yamada Y, Ohe Y, Yoshida T, Minami H, Ohtsu A, Matsumura Y, Saijo N, Okuda H.

Br J Clin Pharmacol. 2010 Aug;70(2):222-33. doi: 10.1111/j.1365-2125.2010.03695.x.

29.

Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.

Sugiyama E, Kaniwa N, Kim SR, Hasegawa R, Saito Y, Ueno H, Okusaka T, Ikeda M, Morizane C, Kondo S, Yamamoto N, Tamura T, Furuse J, Ishii H, Yoshida T, Saijo N, Sawada J.

Clin Pharmacokinet. 2010 Aug;49(8):549-58. doi: 10.2165/11532970-000000000-00000.

PMID:
20608756
30.

Prediction of severe adverse drug reactions using pharmacogenetic biomarkers.

Tohkin M, Ishiguro A, Kaniwa N, Saito Y, Kurose K, Hasegawa R.

Drug Metab Pharmacokinet. 2010;25(2):122-33.

31.

Survival prediction for pancreatic cancer patients receiving gemcitabine treatment.

Matsubara J, Ono M, Honda K, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Shoji A, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T.

Mol Cell Proteomics. 2010 Apr;9(4):695-704. doi: 10.1074/mcp.M900234-MCP200. Epub 2010 Jan 8.

32.

Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients.

Fukushima-Uesaka H, Saito Y, Maekawa K, Kurose K, Sugiyama E, Katori N, Kaniwa N, Hasegawa R, Hamaguchi T, Eguchi-Nakajima T, Kato K, Yamada Y, Shimada Y, Yoshida T, Yamamoto N, Nokihara H, Kunitoh H, Ohe Y, Tamura T, Ura T, Saito M, Muro K, Doi T, Fuse N, Yoshino T, Ohtsu A, Saijo N, Matsumura Y, Okuda H, Sawada J.

Drug Metab Pharmacokinet. 2009;24(6):565-74.

33.

Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene.

Sugiyama E, Lee SJ, Lee SS, Kim WY, Kim SR, Tohkin M, Hasegawa R, Okuda H, Kawamoto M, Kamatani N, Sawada J, Kaniwa N, Saito Y, Shin JG.

Drug Metab Pharmacokinet. 2009;24(6):553-6.

34.

Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.

Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Matsumura Y, Ohtsu A, Saijo N, Minami H.

Cancer Chemother Pharmacol. 2010 May;66(1):95-105. doi: 10.1007/s00280-009-1138-y. Epub 2009 Sep 22.

PMID:
19771428
35.

HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions.

Ikeda H, Takahashi Y, Yamazaki E, Fujiwara T, Kaniwa N, Saito Y, Aihara M, Kashiwagi M, Muramatsu M.

Epilepsia. 2010 Feb;51(2):297-300. doi: 10.1111/j.1528-1167.2009.02269.x. Epub 2009 Aug 19.

36.

Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects.

Maekawa K, Harakawa N, Sugiyama E, Tohkin M, Kim SR, Kaniwa N, Katori N, Hasegawa R, Yasuda K, Kamide K, Miyata T, Saito Y, Sawada J.

Drug Metab Dispos. 2009 Sep;37(9):1895-903. doi: 10.1124/dmd.109.027003. Epub 2009 Jun 18.

PMID:
19541829
37.

Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.

Ueno H, Kaniwa N, Okusaka T, Ikeda M, Morizane C, Kondo S, Sugiyama E, Kim SR, Hasegawa R, Saito Y, Yoshida T, Saijo N, Sawada J.

Br J Cancer. 2009 Mar 24;100(6):870-3. doi: 10.1038/sj.bjc.6604971.

38.

Identification of a predictive biomarker for hematologic toxicities of gemcitabine.

Matsubara J, Ono M, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Honda K, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T.

J Clin Oncol. 2009 May 1;27(13):2261-8. doi: 10.1200/JCO.2008.19.9745. Epub 2009 Mar 16.

PMID:
19289617
39.

Genetic variations and haplotype structures of the glutathione S-transferase genes, GSTT1 and GSTM1, in a Japanese patient population.

Tatewaki N, Maekawa K, Katori N, Kurose K, Kaniwa N, Yamamoto N, Kunitoh H, Ohe Y, Nokihara H, Sekine I, Tamura T, Yoshida T, Saijo N, Saito Y, Sawada J.

Drug Metab Pharmacokinet. 2009;24(1):118-26.

40.

[Exploratory studies on genetic biomarkers related to serious drug adverse reactions].

Kaniwa N, Hasegawa R.

Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 2009;(127):1-14. Review. Japanese.

PMID:
20306701
41.

A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies.

Sato Y, Laird NM, Nagashima K, Kato R, Hamano T, Yafune A, Kaniwa N, Saito Y, Sugiyama E, Kim SR, Furuse J, Ishii H, Ueno H, Okusaka T, Saijo N, Sawada JI, Yoshida T.

Pharmacogenomics J. 2009 Apr;9(2):137-46. doi: 10.1038/tpj.2008.17. Epub 2008 Dec 23.

PMID:
19104505
42.

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis.

Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R; JSAR research group.

Pharmacogenomics. 2008 Nov;9(11):1617-22. doi: 10.2217/14622416.9.11.1617.

PMID:
19018717
43.

Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.

Saito Y, Sai K, Maekawa K, Kaniwa N, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Minami H, Ohtsu A, Matsumura Y, Saijo N, Sawada J.

Drug Metab Dispos. 2009 Feb;37(2):272-6. doi: 10.1124/dmd.108.024208. Epub 2008 Nov 3.

PMID:
18981166
44.

Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK).

Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, Ueno H, Okusaka T, Ikeda M, Morizane C, Yamamoto N, Yoshida T, Kamatani N, Furuse J, Ishii H, Saijo N, Ozawa S, Sawada J.

Drug Metab Pharmacokinet. 2008;23(5):379-84.

45.

Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population.

Sai K, Saito Y, Itoda M, Fukushima-Uesaka H, Nishimaki-Mogami T, Ozawa S, Maekawa K, Kurose K, Kaniwa N, Kawamoto M, Kamatani N, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Minami H, Matsumura Y, Ohtsu A, Saijo N, Sawada J.

Drug Metab Pharmacokinet. 2008;23(2):139-47.

46.

Genetic variations of VDR/NR1I1 encoding vitamin D receptor in a Japanese population.

Ukaji M, Saito Y, Fukushima-Uesaka H, Maekawa K, Katori N, Kaniwa N, Yoshida T, Nokihara H, Sekine I, Kunitoh H, Ohe Y, Yamamoto N, Tamura T, Saijo N, Sawada J.

Drug Metab Pharmacokinet. 2007 Dec;22(6):462-7.

47.

Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15.

Kim SR, Saito Y, Sai K, Kurose K, Maekawa K, Kaniwa N, Ozawa S, Kamatani N, Shirao K, Yamamoto N, Hamaguchi T, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Minami H, Ohtsu A, Saijo N, Sawada J.

Drug Metab Pharmacokinet. 2007 Dec;22(6):456-61.

48.

Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.

Sai K, Saito Y, Sakamoto H, Shirao K, Kurose K, Saeki M, Ozawa S, Kaniwa N, Hirohashi S, Saijo N, Sawada J, Yoshida T.

Cancer Lett. 2008 Mar 18;261(2):165-71. Epub 2007 Dec 20.

PMID:
18082937
49.

Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.

Sai K, Saito Y, Fukushima-Uesaka H, Kurose K, Kaniwa N, Kamatani N, Shirao K, Yamamoto N, Hamaguchi T, Kunitoh H, Ohe Y, Tamura T, Yamada Y, Minami H, Ohtsu A, Yoshida T, Saijo N, Sawada J.

Cancer Chemother Pharmacol. 2008 Aug;62(3):529-37. Epub 2007 Nov 8.

PMID:
17992531
50.

Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences.

Maekawa K, Saeki M, Saito Y, Ozawa S, Kurose K, Kaniwa N, Kawamoto M, Kamatani N, Kato K, Hamaguchi T, Yamada Y, Shirao K, Shimada Y, Muto M, Doi T, Ohtsu A, Yoshida T, Matsumura Y, Saijo N, Sawada J.

J Hum Genet. 2007;52(10):804-19. Epub 2007 Sep 9.

PMID:
17828463

Supplemental Content

Loading ...
Support Center